关于控股股东、实际控制人办理部分股票质押业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 近日，公司接到控股股东、实际控制人曾少贵先生的通知，曾少贵先生办理 了部分股票质押业务。具体事项如下： | 股东名称 | 是否为控股 股东或第一 | 本次质押 | 占其所 持股份 | 占公司 总股本 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 是否为 | 是否为补 | 质押起始 | 质押到期日 | 质权人 | 质押 | | | 大股东及其 | 数量（股） | 比例 | 比例 | 限售股 | 充质押 | 日 | | | 用途 | | | 一致行动人 | | （%） | （%） | | | | | | | | 曾少贵 | 是 | 30,350,000 | 30.80 | 3.44 | - | 否 | 2026/3/27 | 至办理解除质 押登记之日 | 西藏信托有限 公司 | 融资 担保 | | 合 ...

法律意见书 国浩律师（深圳）事务所 关于 深圳翰宇药业股份有限公司 法律意见书 北京·上海·深圳·杭州·广州·昆明·天津·成都·宁波·福州·西安·南京·南宁·济南·重庆 Beijing·Shanghai·Shenzhen·Hangzhou·Guangzhou·Kunming·Tianjin·Chengdu ·Ningbo ·Fuzhou·Xi`an·Nanjing·Nanning·Jinan·Chongqing 苏州·长沙 ·太原·武汉·贵阳·乌鲁木齐·郑州·石家庄·合肥·海南·青岛·南昌·大连·银川·拉孜 Suzhou·Changsha·Taiyuan·Wuhan ·Guiyang·Wulumuqi·Zhengzhou·Shijiazhuang·Hefei·Hainan·Qingdao·Nanchang·Dalian·Yinchuan·Lhatse 香港·巴黎·马德里·硅谷·斯德哥尔摩·纽约·马来西亚·柬埔寨·乌兹别克斯坦·哈萨克斯坦 Hongkong·Paris·Madrid·Silicon Valley·Stockholm·New York·Malaysia·Cambodia·Uzbekistan·Ka ...

证券代码：300199 证券简称：翰宇药业 公告编号：2026-013 深圳翰宇药业股份有限公司 2026年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会没有否决或变更议案的情况发生。 会议召开时间：2026年3月16日（周一）下午15:30 会议地点：深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼会 议室 会议主持人：董事长曾少贵先生 本次会议的召集、召开符合《公司法》《上市公司股东会规则》以及《公 司章程》《股东会议事规则》等的有关规定，合法有效。 2、通过现场和网络投票的股东783人，代表股份193,876,669股，占公司 有表决权股份总数的21.9506%。 2、本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 1、2026年2月13日，深圳翰宇药业股份有限公司（以下简称"公司"或"翰 宇药业"）第六届董事会第十三次会议审议通过《关于提请召开2026年第二次 临时股东会的议案》，详见公司2026年2月26日在中国证监会指定信息披露网 站（http://www.cninfo.com ...

Core Viewpoint - The global GLP-1 raw material market is experiencing rapid growth, driven by the increasing popularity of oral formulations and the expansion of weight loss indications [1] Company Summary - The company has made proactive investments in capacity expansion and is continuously improving its quality system and global compliance certifications [1] - The company is well-prepared to meet market expansion and solidify its leading position in the industry [1] Industry Summary - The overall market size of the GLP-1 sector is expected to continue expanding rapidly [1]

Group 1 - The core viewpoint of the article highlights that the global GLP-1 raw material market is experiencing rapid growth, driven by the increasing popularity of oral formulations and the expansion of weight loss indications [1] - The industry is expected to continue expanding quickly, with the overall market size projected to grow significantly [1] - The company has proactively expanded its production capacity and continuously improved its quality system and global compliance certifications to prepare for market expansion and solidify its leading position in the industry [1]

Group 1 - The research team from the Chinese Academy of Sciences has developed a "histidine scanning method" that can quickly locate key sites on T cell receptors (TCR) responsible for recognizing cancer cells and initiating clearance programs [1] - The modified TCR molecules act as highly sensitive enhanced "security scanners," significantly improving T cells' ability to eliminate cancer cells [1] - This method does not rely on the three-dimensional structural information of TCR molecules, allowing for simultaneous modification of multiple key sites to enhance the ability of TCRs to capture cancer cells [1] Group 2 - The modified T cells exhibit higher activation levels and stronger killing power, with the ability to accurately distinguish between cancerous and healthy cells, thus avoiding collateral damage [1] - The research has shown significant efficacy in animal models, providing a new approach for developing the next generation of efficient and precise cancer immunotherapies [1] - Related A-share concept stocks include Hanyu Pharmaceutical and New Source [2]

Core Viewpoint - The company, Hanyu Pharmaceutical, anticipates a significant improvement in its financial performance for the year 2025, with projected revenues between 950 million and 980 million yuan and a return to profitability with net profits estimated between 40 million and 50 million yuan [1] Financial Performance - For the year 2025, the company expects to achieve operating revenue of 950 million to 980 million yuan [1] - The company forecasts a net profit of 40 million to 50 million yuan, indicating a turnaround from previous losses [1] Strategic Initiatives - In the second half of 2025, the company plans to increase its research and development investments, capacity building, and international expansion to capitalize on the rapid growth opportunities in the GLP-1 global market [1] - The related expenses for these strategic initiatives will be concentrated, but the company maintains a positive outlook on its core business and sufficient operating cash flow [1]

Core Viewpoint - The company announced the decision to change its auditing firm for the fiscal year 2025, pending approval from the shareholders' meeting [2] Group 1 - The company will hold its sixth board meeting on February 13, 2026, to review the proposal regarding the change of the auditing firm [2] - The new auditing firm appointed is Zhengdan Zhiyuan (Shenzhen) Accounting Firm (Special General Partnership) [2] - The proposal to change the auditing firm requires approval from the company's shareholders [2]

Group 1 - Han Yu Pharmaceutical announced that as of the date of the announcement, Zeng Shaogui has pledged a total of 47.19 million shares, accounting for 47.89% of his holdings [1] - Zeng Shaoqiang has pledged approximately 29.16 million shares, representing 46.18% of his holdings [1] - Zeng Shaobin has pledged 12.50 million shares, which is 57.56% of his holdings [1]

2、股东股份累计质押情况 证券代码：300199 证券简称：翰宇药业 公告编号：2026-012 深圳翰宇药业股份有限公司 关于控股股东、实际控制人办理部分股票质押业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 近日，公司接到控股股东、实际控制人曾少强先生的通知，曾少强先生办理 了部分股票质押业务。具体事项如下： | 股东名称 | 是否为控股 股东或第一 | 本次质押 | 占其所 持股份 | 占公司 总股本 | 是否为 | 是否为补 | 质押起始 | 质押到期日 | 质权人 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 一致行动人 | 数量 | 比例 | 比例 | 限售股 | 充质押 | 日 | | | 用途 | | | | | | | | | | 至办理解除质 | 广州银行股份有 | 融资 | | 曾少强 | 是 | 2,659,600 | 4.21 | 0.30 | - | 否 | 2026/2/ ...